Hologic, the Marlborough, Massachusetts medical technology company that focuses on women's health, said on October 19, 2026 that it had signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona. Financial terms were not disclosed.
Reveal Genomics develops genomic tests that help doctors personalise cancer treatment. Its main product, HER2DX, is designed to help optimise therapy for patients with HER2-positive breast cancer. Completion of the deal depends on approval from Spanish regulators and other customary closing conditions, and the companies did not give a target date.
The announcement did not say how Reveal Genomics will be run after the deal closes, whether its Barcelona team will stay in place or whether the company will keep its name.
What Reveal Genomics built
Reveal Genomics describes itself as a biotechnology start-up that wants to change the way biomarkers are used in oncology. According to the boilerplate in Hologic's release, it develops diagnostic tools to identify the best treatment options for people with cancer and uses advanced laboratory techniques, computer applications and machine learning to analyse cancer research data.
HER2DX, which the company's website calls the first genomic tool for patients with HER2-positive breast cancer, is meant to guide therapy decisions for that group of patients. The company's website says the largest prospective trial of a 12-week regimen of chemotherapy plus two HER2-targeted drugs before surgery confirmed that HER2DX predicts response. The company's website also lists other tests, dnaDX and TNBCDX. Capital-riesgo.es reported in December 2025 that HER2DX carried the European CE mark, had entered the US Medicare system and was being used in international medical centres.
“Joining Hologic gives us the scale and capabilities to accelerate that mission and reach many more patients worldwide.”
The founders and the funding
Reveal Genomics was set up in September 2020 as a spin-off of Hospital Clínic and the IDIBAPS research institute, the University of Barcelona and the Vall d'Hebron Institute of Oncology (VHIO), according to a VHIO announcement at the time. Its founders were the oncologist Aleix Prat of Hospital Clínic and the University of Barcelona; Ana Vivancos, head of cancer genomics at VHIO; Charles Perou and Joel Parker of the University of North Carolina at Chapel Hill; and Patricia Villagrasa, then scientific director of the SOLTI breast cancer research group. Villagrasa-Gonzalez is now the company's chief executive.
The company has disclosed little about its funding. In December 2025, Avançsa, the investment arm of the Catalan regional government, signed a strategic agreement with Reveal Genomics valued at €2 million (about $2.3 million) to support its growth and international expansion, Capital-riesgo.es reported. The type of financing was not specified. Reveal Genomics has not published a total for the money it has raised, and its headcount was not disclosed.
Why Hologic is buying
Hologic already sells the Breast Cancer Index, a genomic test that is recognised in clinical guidelines and helps inform decisions about extended endocrine (hormone) therapy for women with early-stage, hormone receptor-positive breast cancer. Hologic said Reveal Genomics' tests were highly complementary to that product and that the combined range would help inform treatment decisions for more women with breast cancer.
Vitor Rocha, who runs Hologic's Diagnostic Solutions division, said the deal showed the company's commitment to innovation and would expand its ability to inform breast cancer treatment decisions. Villagrasa-Gonzalez said she and her co-founders started Reveal Genomics to bring precision oncology closer to patients, and that joining Hologic would give the company the scale to reach many more patients around the world.
Hologic itself is changing hands. In October 2025 it agreed to be taken private by the investment firms Blackstone and TPG in a deal worth up to $79 per share.
Consolidation in cancer diagnostics
Large diagnostics companies have been buying cancer testing businesses this year. Dealroom noted that Abbott completed its purchase of Exact Sciences for about $21 billion in March, and that Roche agreed in April to buy SAGA Diagnostics for up to $595 million.
Compared with those deals, Reveal Genomics is a small addition. It gives Hologic a second breast cancer test aimed at a different group of patients, patients with HER2-positive disease, rather than another product for the hormone receptor-positive cancers its existing test serves.
